These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 17227621)

  • 61. Entrapment of andrographolide in cross-linked alginate pellets: I. Formulation and evaluation of associated release kinetics.
    Shariff A; PK M; KLK P; M M
    Pak J Pharm Sci; 2007 Jan; 20(1):1-9. PubMed ID: 17337420
    [TBL] [Abstract][Full Text] [Related]  

  • 62. An in vitro/in vivo correlation for the disintegration and onset of drug release from enteric-coated pellets.
    Ebel JP; Jay M; Beihn RM
    Pharm Res; 1993 Feb; 10(2):233-8. PubMed ID: 8456070
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Evaluation of poly(styrene-alt-maleic anhydride)-ethanol as enteric coating material.
    Lai X; Sun C; Tian H; Zhao W; Gao L
    Int J Pharm; 2008 Mar; 352(1-2):66-73. PubMed ID: 18054184
    [TBL] [Abstract][Full Text] [Related]  

  • 64. [Precipitation of pH-adjusted local anesthetics with sodium bicarbonate].
    Koitabashi T; Sekiguchi H; Miyao H; Kawasaki J; Kawazoe T
    Masui; 1995 Jan; 44(1):15-20. PubMed ID: 7699818
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Gastrointestinal transit and disintegration of enteric coated magnetic tablets assessed by ac biosusceptometry.
    Corá LA; Romeiro FG; Américo MF; Oliveira RB; Baffa O; Stelzer M; Miranda JR
    Eur J Pharm Sci; 2006 Jan; 27(1):1-8. PubMed ID: 16188432
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Dissolution testing of marketed rifampicin containing fixed dose combination formulations using a new discriminative media: a post marketing retrospective study.
    Panchagnula R; Kumar Bajpai A; Agrawal S; Ashokraj Y
    Pharmazie; 2006 Oct; 61(10):851-4. PubMed ID: 17069424
    [TBL] [Abstract][Full Text] [Related]  

  • 67. A novel system for three-pulse drug release based on "tablets in capsule" device.
    Li B; Zhu J; Zheng C; Gong W
    Int J Pharm; 2008 Mar; 352(1-2):159-64. PubMed ID: 18055142
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Development of nifedipine-loaded coated gelatin microcapsule as a long acting oral delivery.
    Li DX; Kim JO; Oh DH; Lee WS; Hong MJ; Kang JY; Choi JS; Woo JS; Yong CS; Choi HG
    Arch Pharm Res; 2009 Jan; 32(1):127-32. PubMed ID: 19183885
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Assessing the influence of media composition and ionic strength on drug release from commercial immediate-release and enteric-coated aspirin tablets.
    Karkossa F; Klein S
    J Pharm Pharmacol; 2017 Oct; 69(10):1327-1340. PubMed ID: 28703304
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Effect of sodium bicarbonate and sodium starch glycolate on the in vivo disintegration of hard gelatin capsules--a radiological study in the dog.
    Marvola M; Hannula AM; Ojantakanen S; Westermarck E; Rajamäki M
    Acta Pharm Nord; 1989; 1(6):355-62. PubMed ID: 2560378
    [TBL] [Abstract][Full Text] [Related]  

  • 71. In vitro and in vivo evaluation of controlled-release and enteric-coated formulations of sodium salicylate.
    Borgström L; Ekman B; Larsson H; Leden I; Lindahl A; Melander A; Wåhlin-Boll E
    Biopharm Drug Dispos; 1984; 5(3):261-72. PubMed ID: 6487753
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Mechanistic analysis and experimental verification of bicarbonate-controlled enteric coat dissolution: Potential in vivo implications.
    Al-Gousous J; Ruan H; Blechar JA; Sun KX; Salehi N; Langguth P; Job NM; Lipka E; Loebenberg R; Bermejo M; Amidon GE; Amidon GL
    Eur J Pharm Biopharm; 2019 Jun; 139():47-58. PubMed ID: 30872012
    [TBL] [Abstract][Full Text] [Related]  

  • 73. [Tablets in stool? A common problem!].
    Schuerch LV; Nyfeler J; Holder G; Surber C; Haefeli WE
    Schweiz Med Wochenschr; 1999 May; 129(17):670-3. PubMed ID: 10407938
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Enteric-coated cholylsarcosine microgranules for the treatment of short bowel syndrome.
    Fürst T; Bott C; Stein J; Dressman JB
    J Pharm Pharmacol; 2005 Jan; 57(1):53-60. PubMed ID: 15638993
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Mechanistic understanding of underperforming enteric coated products: Opportunities to add clinical relevance to the dissolution test.
    Amaral Silva D; Davies NM; Doschak MR; Al-Gousous J; Bou-Chacra N; Löbenberg R
    J Control Release; 2020 Sep; 325():323-334. PubMed ID: 32649973
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Stability of an extemporaneously compounded cisapride suspension.
    Horn JR; Anderson GD
    Clin Ther; 1994; 16(2):169-72. PubMed ID: 8062312
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Pharmaceutical availability from oral dosage forms: in vitro release of nitrofurantoin from tablets and capsules.
    Senjković R; Kallay N; Vilendecić M
    Pharmazie; 1987 Mar; 42(3):186-8. PubMed ID: 3602077
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Physiologically relevant dissolution conditions towards improved in vitro - in vivo relationship - A case study with enteric coated pantoprazole tablets.
    Amaral Silva D; Gomes Davanço M; Davies NM; Krämer J; de Oliveira Carvalho P; Löbenberg R
    Int J Pharm; 2021 Aug; 605():120857. PubMed ID: 34229072
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Pancreatic enzymes prepared in bicarbonate solution for administration through enteral feeding tubes.
    Boullata AM; Boullata JI
    Am J Health Syst Pharm; 2015 Jul; 72(14):1210-4. PubMed ID: 26150571
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Influence of pH on release of phenytoin sodium from slow-release dosage forms.
    Serajuddin AT; Jarowski CI
    J Pharm Sci; 1993 Mar; 82(3):306-10. PubMed ID: 8450427
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.